Endocrine Abstracts

Background: In Clinical Trials, Glucagon-like peptide-1 (GLP-1) receptor analogs liraglutide and semaglutide have been shown to cause weight loss, reduced systolic blood pressure, effectiveglycemic control with low rates of hypoglycemia, in patients with type 2 diabetes. Through a retrospective clinical study, the authors aimed to assess the clinical effectiveness of GLP-1 receptor agonists in the management of obesity in patients with Type 2 Diabetes.Me...

Background: Bariatric surgery is currently the most effective treatment for weight loss. Its metabolic effects of weight loss and improvement of type 2 diabetes are mediated mainly through the postprandial elevation of gut hormones such as GLP-1, which suppresses food intake and improves insulin secretion.Aim: To characterize the longitudinal changes in fasting and postprandial secretion of glucose, insulin and gut hormones (GLP-1 and GIP) in patients be...

Optimising glycaemic control and reducing risk of associated co-morbidities in the patient with complex diabetes and obesity presents a number of challenges in primary care. This study evaluates weight and HbA1c changes at 12 months (primary outcomes) and blood pressure, lipid and medication changes (secondary outcomes) in people with diabetes referred by the diabetes specialist practice nurse (DSN) to a weight management group. The DSN identified patients who would benefit fr...

Introduction: Lipodystrophy is a rare medical condition with a varied etiology that is characterised by a complete or partial loss of adipose tissue, which can be generalised, partial or localised. Patients have altered secretion of adipokines, such as, Leptin and Adiponectin. Ectopic lipid accumulation is common and leads to metabolic complications associated with insulin resistance (IR) such as, diabetes mellitus (DM) and hypertriglyceridemia. Levels of circulating inflammat...

It is known that a subset of obese individuals do not exhibit features of the metabolic syndrome (Met-S); these are referred to as being metabolically healthy obese (MHO) individuals. Conversely there are other individuals who although have a normal BMI are insulin resistant and exhibit some of the features of the Met-S and are termed as being metabolically unhealthy normal weight (MUHNW) individuals. This study aims to identify the prevalence of metabolic health among a diffe...

Background: The role of weight loss in the management and prevention of type 2 diabetes has grabbed the attention of the media and the NHS, supported by the extremely positive DROPLET trial results. Very Low Calorie Diets (VLCDs) are being recognised as a valuable treatment option for type 2 diabetes, with a qualified healthcare professional closely involved. The NHS has announced plans for a pilot project in 2019 to establish the feasibility of this approach within the NHS st...

Introduction: Type 2 Diabetes Mellitus (T2DM) and obesity are a serious health challenge. Obesity and metabolic disorders are associated with cardiovascular risk. Several studies have suggested that low vitamin D status contributes to insulin resistance. This study aimed to explore vitamin D and its relationship with cardio-metabolic risk factors in those with early T2DM.Methods: Early T2DM subjects (N=139) with early T2DM, ≤ 3 years, were...

Background: Obesity is a public health problem, associated with several non-communicable diseases, lower psychosocial well-being and elevated risk of death. Managing obesity with Orlistat (a lipase inhibitor) has shown gastrointestinal side effects. Seaweed and its extract alginate, have shown lipase inhibition, which could help with weight loss. Therefore, adding alginate or seaweed into a cheese could decrease dietary lipids digestion and absorption and therefore reducing bo...

Post–bariatric surgery hypoglycaemia (PBH) is a metabolic complication of bariatric surgery. Symptoms of post-bariatric hyperinsulinaemic hypoglycaemia may develop from 6 months to years after surgery, and typically present 1 to 3 hours after a meal. The incidence of post bariatric hypoglycaemia is estimated to be 0.2–11%,1,4 but the actual incidence is unknown due to the vague symptoms and lack of diagnostic criteria for the diagnosis of post-bariatric hy...